Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan slashes B&M price target after update, reiterates 'underweight'

(Sharecast News) - JPMorgan Cazenove slashed its price target on B&M European Value Retail on Wednesday to 207p from 281p and reiterated its 'underweight' rating following the discount retailer's trading update a day earlier. "Our concerns mount following the 1Q26 trading update shared by B&M yesterday," the bank said.

"First, UK LFL came in at +1.3% (versus 2.5-3% Street expectations and JPMe at 5%), which suggests very weak sales densities in the context of ongoing space addition," it said.

JPM said the underlying trends are even more concerning in the context of weather and calendar tailwinds in the period, while the LFL outcome implies a very meaningful gap versus other reporters, across grocery and general retail.

"Second, the absence of an FY26 outlook at this point (only reporter amongst peer group) is reflective of the lack of visibility and action plan, in our view," JPM said.

"Third, and perhaps most important, we are not yet convinced that management are focused on addressing what we see as the most challenging aspects of the investment case, at least for the time being."

The bank said it was revising its expectations down to reflect a more acute price-reset needed to revamp LFLs, sitting around double digit percentage below the Street.

JPM said it continues to prefer Sainsbury and Tesco, both of which are rated 'overweight', as more visible investment cases in the UK.

At 0808 BST, B&M shares were down 0.9% at 232.14p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.